A Top Biotech CEO In Cancer Treatments: F-star Therapeutics CEO Eliot Forster
03.30.21
Interviews

Eliot Forster is the Chief Executive Officer of F-star Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer. To date, the company has built a comprehensive IP estate, with over 200 issued patents and more than 60 pending applications, many of which have blockbuster potential.

In this conversation, we discuss Eliot’s career as a corporate executive in big pharma as well as his transition to and leadership experience in venture and growth stage biotech. Before coming to F-star in 2018, he served as chief executive officer of Immunocore and prior to that, he held executive positions at Creabilis Therapeutics, Solace Pharmaceuticals, and Pfizer.

We also explore the broader biotech industry in the context of private company investing as well as the specifics of F-star’s drug development programs.

We hope you enjoy the show.

Listen on iTunes or Google Podcasts.

Insights & Capital

Discover unique insights from leading executives and growth investors.

Sign up for our weekly newsletter.

Top Go Back
© 2020 GrowthCap, LLC. All rights reserved.

Sign up for GrowthCap Insights